Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMRN, NBIX, ABVX, UTHR, ELVN, and represent 33.03% of Vestal Point Capital's stock portfolio.
- Added to shares of these 10 stocks: UTHR (+$195M), BMRN (+$140M), ABT (+$127M), ABVX (+$113M), NBIX (+$106M), ZBH (+$104M), ASND (+$100M), PODD (+$94M), AZN (+$66M), IRON (+$62M).
- Started 11 new stock positions in RZLT, SGMT, ABT, ENGN, EVMN, Kailera Therapeutics, AVTX, IBIO, ASND, TRAX. INSM.
- Reduced shares in these 10 stocks: RVMD (-$361M), APGE (-$93M), Ascendis Pharma A S (-$86M), RGEN (-$72M), SRRK (-$65M), ARWR (-$57M), VERA (-$55M), TERN (-$53M), BSX (-$50M), NUVL (-$49M).
- Sold out of its positions in ABSI, AGIO, APGE, ARVN, Ascendis Pharma A S, BSX, CADL, CLDX, COGT, CYTK.
- Vestal Point Capital was a net buyer of stock by $53M.
- Vestal Point Capital has $4.3B in assets under management (AUM), dropping by 19.64%.
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 68 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) | 8.1 | $345M | +68% | 6.0M | 57.22 |
|
| Neurocrine Biosciences (NBIX) | 7.4 | $317M | +50% | 1.9M | 168.53 |
|
| Abivax SA Sponsored Ads (ABVX) | 7.3 | $313M | +56% | 2.3M | 133.26 |
|
| United Therapeutics Corporation (UTHR) | 5.5 | $236M | +480% | 435k | 541.83 |
|
| Enliven Therapeutics (ELVN) | 4.7 | $203M | +23% | 4.0M | 50.75 |
|
| Nurix Therapeutics (NRIX) | 4.6 | $195M | +23% | 8.1M | 24.26 |
|
| Bicara Therapeutics (BCAX) | 3.6 | $156M | -3% | 5.3M | 29.69 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 3.1 | $132M | +7% | 19M | 6.81 |
|
| Arrowhead Pharmaceuticals (ARWR) | 3.0 | $128M | -30% | 1.6M | 81.51 |
|
| Abbott Laboratories (ABT) | 3.0 | $127M | NEW | 1.4M | 90.74 |
|
| Zimmer Holdings (ZBH) | 2.8 | $121M | +636% | 1.4M | 86.09 |
|
| Disc Medicine (IRON) | 2.6 | $113M | +121% | 1.6M | 73.14 |
|
| Monte Rosa Therapeutics (GLUE) | 2.6 | $111M | +27% | 4.6M | 24.20 |
|
| Insulet Corporation (PODD) | 2.4 | $102M | +1224% | 670k | 152.25 |
|
| Ascendis Pharma A/S Ord Shs (ASND) | 2.3 | $100M | NEW | 375k | 266.72 |
|
| AstraZeneca Ord (AZN) | 2.0 | $85M | +350% | 450k | 189.62 |
|
| Sanofi SA Sponsored Adr (SNY) | 2.0 | $85M | +42% | 2.0M | 42.66 |
|
| Revolution Medicines (RVMD) | 2.0 | $84M | -81% | 450k | 187.28 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.9 | $83M | +18% | 8.3M | 10.00 |
|
| Dyne Therapeutics (DYN) | 1.8 | $75M | -15% | 3.4M | 22.21 |
|
| Nektar Therapeutics Com New (NKTR) | 1.6 | $70M | +250% | 1.0M | 69.81 |
|
| Globus Medical Cl A (GMED) | 1.6 | $67M | +39% | 850k | 79.01 |
|
| Tarsus Pharmaceuticals (TARS) | 1.5 | $66M | +425% | 1.1M | 62.94 |
|
| Immatics NV SHS (IMTX) | 1.5 | $63M | 6.2M | 10.13 |
|
|
| Trevi Therapeutics (TRVI) | 1.4 | $58M | +43% | 3.1M | 18.65 |
|
| Immunocore Holdings Ads (IMCR) | 1.3 | $57M | -34% | 1.8M | 31.75 |
|
| Repligen Corporation (RGEN) | 1.3 | $55M | -56% | 400k | 136.44 |
|
| Bristol Myers Squibb (BMY) | 1.1 | $46M | -20% | 800k | 57.62 |
|
| uniQure NV SHS (QURE) | 1.0 | $43M | +160% | 935k | 46.06 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $42M | +9% | 700k | 60.36 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.9 | $38M | +10% | 545k | 70.20 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.8 | $35M | +106% | 65k | 536.95 |
|
| Alcon Ord Shs (ALC) | 0.8 | $34M | -37% | 500k | 67.10 |
|
| Myriad Genetics (MYGN) | 0.8 | $33M | +247% | 5.7M | 5.71 |
|
| Rapport Therapeutics (RAPP) | 0.7 | $30M | -49% | 730k | 41.67 |
|
| Crescent Biopharma (CBIO) | 0.7 | $29M | +8% | 1.6M | 18.00 |
|
| GE HealthCare Technologies Common Stock (GEHC) | 0.7 | $29M | +80% | 450k | 64.01 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $27M | NEW | 250k | 106.62 |
|
| Viking Therapeutics (VKTX) | 0.6 | $27M | -25% | 680k | 39.01 |
|
| Beta Bionics (BBNX) | 0.6 | $25M | -27% | 1.6M | 15.67 |
|
| Regeneron Pharmaceuticals (REGN) | 0.6 | $25M | 40k | 623.54 |
|
|
| Solid Biosciences Com New (SLDB) | 0.5 | $22M | -56% | 2.2M | 9.99 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.5 | $21M | -61% | 785k | 26.39 |
|
| First Tracks Biotherapeutics I Ord Shs (TRAX) | 0.5 | $20M | NEW | 1.0M | 20.12 |
|
| Lexeo Therapeutics (LXEO) | 0.5 | $20M | -3% | 4.3M | 4.66 |
|
| Savara (SVRA) | 0.4 | $17M | +4% | 2.7M | 6.16 |
|
| Damora Therapeutics Com New (DMRA) | 0.3 | $15M | -4% | 575k | 26.01 |
|
| SpyGlass Pharma Com Shs (SGP) | 0.3 | $15M | 670k | 22.26 |
|
|
| Tectonic Therapeutic (TECX) | 0.3 | $15M | +29% | 425k | 34.38 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $14M | NEW | 775k | 18.48 |
|
| Evommune Com Shs (EVMN) | 0.3 | $13M | NEW | 1.0M | 13.29 |
|
| Kailera Therapeutics Common Stock | 0.3 | $13M | NEW | 575k | 22.03 |
|
| Anteris Technologies Global (AVR) | 0.2 | $9.9M | -11% | 1.0M | 9.85 |
|
| Zenas Biopharma (ZBIO) | 0.2 | $9.3M | +82% | 365k | 25.38 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $9.2M | -12% | 2.6M | 3.50 |
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.2 | $8.3M | 1.8M | 4.56 |
|
|
| Surrozen Com New (SRZN) | 0.2 | $7.9M | -10% | 305k | 25.95 |
|
| Monopar Therapeutics Com New (MNPR) | 0.2 | $7.0M | +15% | 76k | 92.59 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.2 | $6.9M | +129% | 1.2M | 5.90 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $5.2M | -2% | 419k | 12.51 |
|
| Palisade Bio (PALI) | 0.1 | $5.2M | 2.5M | 2.09 |
|
|
| iBio Com New (IBIO) | 0.1 | $4.6M | NEW | 2.6M | 1.75 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $4.1M | NEW | 536k | 7.73 |
|
| Engene Therapeutics (ENGN) | 0.1 | $2.9M | NEW | 1.7M | 1.73 |
|
| Rezolute Com New (RZLT) | 0.0 | $2.0M | NEW | 383k | 5.20 |
|
| Nyxoah SA SHS (NYXH) | 0.0 | $1.4M | -2% | 844k | 1.69 |
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $778k | 53k | 14.55 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $281k | 350k | 0.80 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2026 Q2 filed Aug. 14, 2026
- Vestal Point Capital 2026 Q1 filed May 15, 2026
- Vestal Point Capital 2025 Q4 filed Feb. 17, 2026
- Vestal Point Capital 2025 Q3 filed Nov. 14, 2025
- Vestal Point Capital 2025 Q2 filed Aug. 14, 2025
- Vestal Point Capital 2025 Q1 filed May 15, 2025
- Vestal Point Capital 2024 Q4 filed Feb. 14, 2025
- Vestal Point Capital 2024 Q3 filed Nov. 14, 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024